Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

Microscopic view of Ebola Virus

Oxford’s Ebola vaccine candidate has been shipped to Uganda, just 80 days after WHO declared a Sudan ebola virus outbreak, having been manufactured by its partner the Serum Institute of India and working in close partnership with the WHO.

Following presentation of key data to the WHO generated in Oxford by Professor Lambe's team, it was announced on 17th November that the vaccine had been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda. The WHO working in partnership with the Ugandan government and Ministry of Health have enabled the ring vaccination trial as part of a multi-faceted effort to curb the outbreak and save lives.

The Oxford team led by Professor Lambe have been working on the vaccine for some time, including ongoing clinical trials in Oxford and Tanzania; manufacture scale-up was led by the Serum Institute and supported by Professor Sandy Douglas of the Jenner Institute. This research was funded by the Department of Health and Social Care (DHSC). SII (Serum Institute of India), who also partnered with the University to manufacture the Covid vaccine, produced 40,000 doses for the trial in just a few short weeks.

Read the full story on the University of Oxford website

Similar stories

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Professor Sir Chris Whitty brings greater understanding of epidemics to Oxford

Chief Medical Officer of England Professor Sir Chris Whitty KCB FMedSci delivers the Sherrington Prize Lecture: Public Understanding of Science to an audience of Oxford staff and students.

Multiple Debilitating Pains – New global study shows the experience of Endometriosis is rooted in a person’s genetics

Researchers at the University of Oxford in collaboration with 25 teams across the world have published the largest study to date of the genetic basis of endometriosis.

Study shows delaying treatment for localised prostate cancer does not increase mortality risk

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind.

Showcasing Oxford’s translational research for Rare Disease Day

Rare Disease Day is an annual awareness day that aims to educate and raise awareness for the 400 million people worldwide who live with a rare disease.

Prostate cancer AI diagnosis tool begins evaluation in Oxford

New artificial intelligence software that can help to spot prostate cancer is being trialled by researchers at Oxford University Hospitals (OUH) NHS Foundation Trust.